The introduction of oral GLP-1 medicines, alongside growing awareness of injectable treatments such as Wegovy and Mounjaro, means patients now have more choice than ever before. Demand for the pills has increased by 350% since the launch in July.
That’s undoubtedly positive, but it has also created a new challenge – increasingly, patients are asking whether they should switch, which option is ‘best’, or whether what they’ve seen online is actually true.
As clinicians, we’re no longer simply helping patients access treatment. We’re helping them navigate an increasingly complex landscape where headlines, social media and anecdotal experiences often sit alongside clinical evidence. Our role in providing clear, personalised guidance has never been more important.
Check out the rest of the feature here
